Frederic Jacques de Bure
Director/Miembro de la Junta en Inpellis, Inc. .
Perfil
Frederic Jacques de Bure is an Independent Director at Inpellis, Inc. and a General Partner at Nusantara Ventures Singapore Pte Ltd.
He was previously a Non-Affiliated Director at PT Visi Media Asia Tbk.
Mr. de Bure holds an MBA from The University of Chicago and an undergraduate degree from Vassar College.
Cargos activos de Frederic Jacques de Bure
| Empresas | Cargo | Inicio |
|---|---|---|
| Nusantara Ventures Singapore Pte Ltd. | Corporate Officer/Principal | 01/01/2009 |
Inpellis, Inc.
 Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ. | Director/Miembro de la Junta | 01/01/2015 |
Antiguos cargos conocidos de Frederic Jacques de Bure.
| Empresas | Cargo | Fin |
|---|---|---|
| PT VISI MEDIA ASIA TBK | Corporate Officer/Principal | 20/03/2012 |
Formación de Frederic Jacques de Bure.
| The University of Chicago | Masters Business Admin |
| Vassar College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| PT VISI MEDIA ASIA TBK | Consumer Services |
| Empresas privadas | 2 |
|---|---|
| Nusantara Ventures Singapore Pte Ltd. | |
Inpellis, Inc.
Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Frederic Jacques de Bure
